Looking ahead to the "epidemic" : Five major issues that China's biopharmaceutical enterprises need to pay attention to

Some might worry that this process will be slowed by the coronavirus pandemic, but in fact, the current situation may actually increase China's attractiveness to large biopharmaceutical companies. China is the first country to largely emerge from the pandemic and is already supporting the development of the healthcare sector. Given the state of public finances in the five EU markets that are deeply affected by COVID-19, we expect healthcare budgets to tighten or further cost control measures to be introduced. In general, China is expected to come out of the difficulties ahead of time, and its biopharmaceutical market will become more attractive to foreign companies.

Given that the epidemic is still spreading globally, and the possibility of another outbreak in China cannot be completely ruled out, it is still too early to draw conclusions about the impact of COVID-19 on China. Some of my points may soon not apply. But overall, I think the COVID-19 epidemic will accelerate the reform of China's medical market, patients will have more convenient channels and better treatment results, and industry players will have broader development opportunities.